Elevated Serum Interleukin-15 Levels in Systemic Lupus Erythematosus

YongBeom Park, Dong Soo Kim, Won Ki Lee, Chang Hee Suh, Soo Kon Lee

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

Interleukin-15 (IL-15) has multiple biological properties, including the induction of other cytokine production and the inhibition of T cell apoptosis. Recently, IL-15 was reported to have a major role in synovial inflammation of rheumatoid arthritis, and that it provokes and amplifies the inflammatory process through the activation of TNF- α production. In systemic lupus erythematosus (SLE), the dysregulation of apoptosis and various cytokine production were observed and have been implicated in the pathogenesis of SLE. Thus, we tried to determine serum IL-15 levels in SLE patients and to assess the relationship among IL-15 levels, TNF- α levels and disease activity of SLE. Twenty SLE patients and 10 controls were studied. Paired serum samples were collected from all SLE patients at the time of presentation with active disease and at 4 weeks after institution of treatment. IL-15 levels were determined by ELISA and compared with the disease activity indices in SLE. The disease activity of SLE was measured using the SLE Disease Activity Index (SLEDAI) and laboratory parameters such as circulating immune complex (CIC), C3, C4, anti-DNA antibody, IgG, IgM, and IgA. The IL-15 levels in SLE patients were significantly higher than those of controls (5.38±4.89 vs. 1.04±1.26 pg/ml). However, elevated IL-15 levels did not correlate with the SLEDAI, nor did they correlate with other laboratory activity indices. The changes in serum IL-15 levels did not correlate with the changes in serum TNF- α in the disease course of SLE patients, whereas TNF- α reflected the changes in disease activity of SLE. Serum levels of IL-15 are elevated in SLE patients, but IL-15 did not correlate with the disease activity of SLE. TNF- α production in SLE patients was unlikely to be related with IL-15.

Original languageEnglish
Pages (from-to)343-348
Number of pages6
JournalYonsei medical journal
Volume40
Issue number4
DOIs
Publication statusPublished - 1999 Jan 1

Fingerprint

Interleukin-15
Systemic Lupus Erythematosus
Serum
Apoptosis
Cytokines
Antinuclear Antibodies
Antigen-Antibody Complex

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Park, YongBeom ; Kim, Dong Soo ; Lee, Won Ki ; Suh, Chang Hee ; Lee, Soo Kon. / Elevated Serum Interleukin-15 Levels in Systemic Lupus Erythematosus. In: Yonsei medical journal. 1999 ; Vol. 40, No. 4. pp. 343-348.
@article{a4dff166af8644409ef5c2ce02d52fc4,
title = "Elevated Serum Interleukin-15 Levels in Systemic Lupus Erythematosus",
abstract = "Interleukin-15 (IL-15) has multiple biological properties, including the induction of other cytokine production and the inhibition of T cell apoptosis. Recently, IL-15 was reported to have a major role in synovial inflammation of rheumatoid arthritis, and that it provokes and amplifies the inflammatory process through the activation of TNF- α production. In systemic lupus erythematosus (SLE), the dysregulation of apoptosis and various cytokine production were observed and have been implicated in the pathogenesis of SLE. Thus, we tried to determine serum IL-15 levels in SLE patients and to assess the relationship among IL-15 levels, TNF- α levels and disease activity of SLE. Twenty SLE patients and 10 controls were studied. Paired serum samples were collected from all SLE patients at the time of presentation with active disease and at 4 weeks after institution of treatment. IL-15 levels were determined by ELISA and compared with the disease activity indices in SLE. The disease activity of SLE was measured using the SLE Disease Activity Index (SLEDAI) and laboratory parameters such as circulating immune complex (CIC), C3, C4, anti-DNA antibody, IgG, IgM, and IgA. The IL-15 levels in SLE patients were significantly higher than those of controls (5.38±4.89 vs. 1.04±1.26 pg/ml). However, elevated IL-15 levels did not correlate with the SLEDAI, nor did they correlate with other laboratory activity indices. The changes in serum IL-15 levels did not correlate with the changes in serum TNF- α in the disease course of SLE patients, whereas TNF- α reflected the changes in disease activity of SLE. Serum levels of IL-15 are elevated in SLE patients, but IL-15 did not correlate with the disease activity of SLE. TNF- α production in SLE patients was unlikely to be related with IL-15.",
author = "YongBeom Park and Kim, {Dong Soo} and Lee, {Won Ki} and Suh, {Chang Hee} and Lee, {Soo Kon}",
year = "1999",
month = "1",
day = "1",
doi = "10.3349/ymj.1999.40.4.343",
language = "English",
volume = "40",
pages = "343--348",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Elevated Serum Interleukin-15 Levels in Systemic Lupus Erythematosus. / Park, YongBeom; Kim, Dong Soo; Lee, Won Ki; Suh, Chang Hee; Lee, Soo Kon.

In: Yonsei medical journal, Vol. 40, No. 4, 01.01.1999, p. 343-348.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Elevated Serum Interleukin-15 Levels in Systemic Lupus Erythematosus

AU - Park, YongBeom

AU - Kim, Dong Soo

AU - Lee, Won Ki

AU - Suh, Chang Hee

AU - Lee, Soo Kon

PY - 1999/1/1

Y1 - 1999/1/1

N2 - Interleukin-15 (IL-15) has multiple biological properties, including the induction of other cytokine production and the inhibition of T cell apoptosis. Recently, IL-15 was reported to have a major role in synovial inflammation of rheumatoid arthritis, and that it provokes and amplifies the inflammatory process through the activation of TNF- α production. In systemic lupus erythematosus (SLE), the dysregulation of apoptosis and various cytokine production were observed and have been implicated in the pathogenesis of SLE. Thus, we tried to determine serum IL-15 levels in SLE patients and to assess the relationship among IL-15 levels, TNF- α levels and disease activity of SLE. Twenty SLE patients and 10 controls were studied. Paired serum samples were collected from all SLE patients at the time of presentation with active disease and at 4 weeks after institution of treatment. IL-15 levels were determined by ELISA and compared with the disease activity indices in SLE. The disease activity of SLE was measured using the SLE Disease Activity Index (SLEDAI) and laboratory parameters such as circulating immune complex (CIC), C3, C4, anti-DNA antibody, IgG, IgM, and IgA. The IL-15 levels in SLE patients were significantly higher than those of controls (5.38±4.89 vs. 1.04±1.26 pg/ml). However, elevated IL-15 levels did not correlate with the SLEDAI, nor did they correlate with other laboratory activity indices. The changes in serum IL-15 levels did not correlate with the changes in serum TNF- α in the disease course of SLE patients, whereas TNF- α reflected the changes in disease activity of SLE. Serum levels of IL-15 are elevated in SLE patients, but IL-15 did not correlate with the disease activity of SLE. TNF- α production in SLE patients was unlikely to be related with IL-15.

AB - Interleukin-15 (IL-15) has multiple biological properties, including the induction of other cytokine production and the inhibition of T cell apoptosis. Recently, IL-15 was reported to have a major role in synovial inflammation of rheumatoid arthritis, and that it provokes and amplifies the inflammatory process through the activation of TNF- α production. In systemic lupus erythematosus (SLE), the dysregulation of apoptosis and various cytokine production were observed and have been implicated in the pathogenesis of SLE. Thus, we tried to determine serum IL-15 levels in SLE patients and to assess the relationship among IL-15 levels, TNF- α levels and disease activity of SLE. Twenty SLE patients and 10 controls were studied. Paired serum samples were collected from all SLE patients at the time of presentation with active disease and at 4 weeks after institution of treatment. IL-15 levels were determined by ELISA and compared with the disease activity indices in SLE. The disease activity of SLE was measured using the SLE Disease Activity Index (SLEDAI) and laboratory parameters such as circulating immune complex (CIC), C3, C4, anti-DNA antibody, IgG, IgM, and IgA. The IL-15 levels in SLE patients were significantly higher than those of controls (5.38±4.89 vs. 1.04±1.26 pg/ml). However, elevated IL-15 levels did not correlate with the SLEDAI, nor did they correlate with other laboratory activity indices. The changes in serum IL-15 levels did not correlate with the changes in serum TNF- α in the disease course of SLE patients, whereas TNF- α reflected the changes in disease activity of SLE. Serum levels of IL-15 are elevated in SLE patients, but IL-15 did not correlate with the disease activity of SLE. TNF- α production in SLE patients was unlikely to be related with IL-15.

UR - http://www.scopus.com/inward/record.url?scp=0033174339&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033174339&partnerID=8YFLogxK

U2 - 10.3349/ymj.1999.40.4.343

DO - 10.3349/ymj.1999.40.4.343

M3 - Article

VL - 40

SP - 343

EP - 348

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -